From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

Drugs that mimic GLP-1 are widely used to treat diabetes and obesity, but it is not fully understood exactly how they produce many of their beneficial effects. Investigators from The Salk Institute ...

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and ...

GLP-1 receptor agonists may confer neuroprotection via reduced neuroinflammation, inhibited apoptosis, and vasodilatory effects that enhance cerebral perfusion through cAMP and VEGF-related pathways.

U ntil the past decade or so, the most common treatments for obesity were diet, exercise, and oral weight loss drugs. But with the introduction of GLP‑1 and dual GIP/GLP-1 agonists, people with ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) are common and burdensome for patients, families, and health systems,12 yet ...

Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...